SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share; Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XI’AN, CHINA – August 17, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2010 Highlights · Revenue increases]